QIAGEN GmbH
QIAGEN GmbH — FDA 510(k) Submissions
QIAGEN GmbH has submitted 13 FDA 510(k) premarket notifications since 2012, of which 13 received clearance as substantially equivalent to a predicate device.
The company's most frequent device categories include Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-based Assay System, Multi-target Respiratory Specimen Nucleic Acid Test Including Sars-cov-2 And Other Microbial Agents, Respiratory Virus Panel Nucleic Acid Assay System, Meningitis/encephalitis Pathogen Multiplex Nucleic Acid Detection System, Real Time Nucleic Acid Amplification System . Use the specialty filter in the sidebar to narrow results.